Record Breaking Attendance at AMMF's International Cholangiocarcinoma Conference 2018
A record number of delegates from across the world were present at what is fast becoming a key annual conference within the UK and Europe to highlight the latest medical advances for the world's second most common primary liver cancer, cholangiocarcinoma.
Stansted Essex, UK, May 23, 2018 (Newswire.com) - May 23, 2018 (Newswire) -The AMMF Cholangiocarcinoma Conference 2018, which this year took place on 10 May at the Radisson Blue Hotel in Stansted Essex, was once again hosted by AMMF, the only charity in the UK dedicated to cholangiocarcinoma (bile duct cancer).
As well as Patient Speakers sharing their own personal experience with the little-known cancer, Specialist Presenters shared latest updates on issues ranging from surgery for cholangiocarcinoma to the latest clinical trials and targeted therapies for the cancer, including the use of radiation therapy (RT).
AMMF's 2018 conference was an emotionally charged, but highly motivating day, hearing how cholangiocarcinoma takes and changes lives. Today we get back in the lab reinvigorated (as if that was needed) to push for better treatments, and more research.
Professor David Bates, Professor of Oncology, Faculty of Medicine & Health Sciences, University of Nottingham School of Medicine
A highlight at this year’s event was the official presentation of the new AMMF Cholangiocarcinoma Scholarship, a 3-year PhD award funded by the charity. Mollie Wilson, the first recipient of the Scholarship, will be based at The Boulter Lab at the University of Edinburgh’s MRC Human Genetics Unit, where she will specifically investigate the role of mutations in cholangiocarcinoma. The Boulter Lab is rapidly establishing itself as one of the UK’s foremost laboratories researching cholangiocarcinoma.
Commenting on the new Scholarship, Mollie says, “I have been very fortunate to be awarded the AMMF Cholangiocarcinoma Scholarship as this will give me the opportunity to conduct vital research towards discovering new ways to overcome this devastating cancer. I look forward to working with the team at the Boulter Lab from October.”
In addition to the presentation of treatment updates, three break-out presentations specifically for patients and carers, were held during the course of the one-day event.
Sponsors at this year’s Conference included Agios Pharmaceuticals, NuCana Plc, Incyte, PCI Biotech, Sirtex and TPM Medical.
Commenting on the Conference, AMMF CEO Helen Morement explains, “The aim, as always, was to discuss cholangiocarcinoma from a multidisciplinary perspective and I believe we succeeded. It was a highly rewarding event and we have received positive feedback from both conference participants and our sponsors. This year has seen a substantial rise in the interest in the conference and in the numbers attending and, given the increasing incidence of cholangiocarcinoma globally, we may well see the Conference move from being a one-day event to two days or more next year. It is a key platform for international experts to share news and information about clinical studies and latest research and for patients and their loved ones to hear about the work that’s taking place to deliver improved diagnostic techniques, treatments, and ultimately a cure, for this devastating cancer.”